Health economic costs of COPD in Sweden by disease severity - Has it changed during a ten years period?

Respiratory Medicine

Volumn 107, Issue 12, 2013, Pages 1931-1938

  Jansson, Sven Arne ^a,b   Backman, Helena ^a   Stenling, Anna ^c   Lindberg, Anne ^a,b   Rönmark, Eva ^a,b   Lundbäck, Bo ^a,d  

^a OLIN Studies   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

COPD; Cost analysis; Health economic aspects of COPD

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MEDICAL LEAVE; PRIORITY JOURNAL; RETIREMENT; SWEDEN;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; CI; CONFIDENCE INTERVAL; COPD; COST ANALYSIS; FEV(1); FORCED EXPIRATORY VOLUME IN 1 S; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE; GOLD; HEALTH ECONOMIC ASPECTS OF COPD; OBSTRUCTIVE LUNG DISEASE IN NORTHERN SWEDEN; OLIN; SEK; SWEDISH KRONA;

ADULT; AGED; AGED, 80 AND OVER; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; SWEDEN;

EID: 84890312664     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.07.012     Document Type: Article

References (37)

1. D.M. Mannino, and A.S. Buist Global burden of COPD: risk factors, prevalence, and future trends Lancet 370 2007 765 773
2. B. Lundbäck, A. Lindberg, M. Lindström, E. Rönmark, A.C. Jonsson, and E. Jönsson Not 15 but 50 percent of smokers develop COPD? - report from the obstructive lung disease in Northern Sweden studies Respir Med 97 2003 115 122
3. G. Viegi, F. Pistelli, D.L. Sherrill, S. Maio, S. Baldacci, and L. Carrozzi Definition, epidemiology and natural history of COPD Eur Respir J 30 2007 993 1013
4. R.J. Halbert, J.L. Natoli, A. Gano, E. Badamgarav, A.S. Buist, and D.M. Mannino Global burden of COPD: systematic review and meta-analysis Eur Respir J 28 2006 523 532
5. A. Lindberg, A. Bjerg, E. Rönmark, L.G. Larsson, and B. Lundbäck Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Respir Med 100 2006 264 272
6. P. Danielsson, I.S. Olafsdottir, B. Benediktsdottir, T. Gislason, and C. Janson The prevalence of chronic obstructive pulmonary disease in Uppsala, Sweden - the Burden of Obstructive Lung Disease (BOLD) study: cross-sectional population-based study Clin Respir J 6 2012 120 127
7. S.A. Jansson, F. Andersson, S. Borg, A. Ericsson, E. Jönsson, and B. Lundbäck Costs of COPD in Sweden according to disease severity Chest 122 2002 1994 2002
8. R. Nielsen, A. Johannessen, B. Benediktsdottir, T. Gislason, A.S. Buist, and A. Gulsvik Present and future costs of COPD in Iceland and Norway: results from the BOLD study Eur Respir J 34 2009 850 857
9. R. Nielsen, A. Johannessen, E.R. Omenaas, P.S. Bakke, J.E. Askildsen, and A. Gulsvik Excessive costs of COPD in ever-smokers. A longitudinal community study Respir Med 105 2011 485 493
10. L. Bilde, A. Rud Svenning, J. Dollerup, H. Baekke Borgeskov, and P. Lange The cost of treating patients with COPD in Denmark - a population study of COPD patients compared with non-COPD controls Respir Med 101 2007 539 546
11. S.D. Ramsey, and S.D. Sullivan The burden of illness and economic evaluation for COPD Eur Respir J 41 S 2003 29 35
12. M. Miravitlles, C. Murio, T. Guerrero, and R. Gisbert Costs of chronic bronchitis and COPD: a 1-year follow-up study Chest 123 2003 784 791
13. B.R. Luce, and A. Elixhauser Standards for socioeconomic evaluations of health care products and services 1990 Springer-Verlag Berlin
14. Statistics Sweden Consumer price index (CPI) fixed index numbers, 1980 = 100 Feb 17, 2011 http://www.scb.se/ [accessed 12.05.11]
15. A. Lindberg, and B. Lundbäck The Obstructive Lung Disease in Northern Sweden Chronic Obstructive Pulmonary Disease Study: design, the first year participation and mortality Clin Respir J 2 S1 2008 64 71
16. K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, A.S. Buist, and P. Calverley Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 176 2007 Sep. 15 532 555
17. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management. html) [accessed 25.01.13].
18. C. Evans, and B. Crawford Patient self-reports in pharmacoeconomic studies PharmacoEconomics 15 1999 241 256
19. M.P.M.H. Rutten-Van Mölken, E.K.A. Van Doorslaer, and R.C.J.A. Van Vliet Statistical analysis of cost outcomes in a randomized controlled clinical trial Health Econ 3 1994 333 345
20. Sveriges Riksbank (www.riksbank.se) [accessed 22.06.11].
21. The Northern County Councils Regional Federation (www.norrlandstingen.se) [accessed 23.12.10].
22. The Dental and Pharmaceutical Benefits Agency (www.tlv.se) [accessed 23.12.10].
23. Statistics Sweden Average monthly salary and basic salary in the whole economy Sept 2, 2010 http://www.scb.se/ [accessed 05.04.11]
24. Confederation of Swedish Enterprise (www.svensktnaringliv.se) [accessed 23.01.11].
25. Swedish Association of Local Authorities and Regions (www.skl.se) [accessed 23.01.11].
26. Swedish Agency for Government Employers (www.arbetsgivarverket.se) [accessed 23.01.11].
27. B. Liljas How to calculate indirect costs in economic evaluations PharmacoEconomics 13 1998 1 7
28. The Dental and Pharmaceutical Benefits Agency General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2) April 24, 2003 http://www.tlv.se/Upload/English/ENG-lfnar-2003-2.pdf [accessed 25.01.13]
29. J.S.U. Hjort Computer intensive statistical methods, validation, model, selection, and bootstrap 1994 Chapman and Hall London
30. The National Board of Health and Welfare. Diagnoses in in-patient care. (www.socialstyrelsen.se) [accessed 13.04.11].
31. M. Britton The burden of COPD in the U.K.: results from the confronting COPD survey Respir Med 97 S 2003 71 79
32. M.T. Halpern, R.H. Stanford, and R. Borker The burden of COPD in the U.S.A.: results from the Confronting COPD survey Respir Med 97 S 2003 81 89
33. S. Boulenger, J. Nixon, M. Drummond, P. Ulmann, S. Rice, and G. de Pouvourville Can economic evaluations be made more transferable? Eur J Health Econ 6 2005 334 346
34. D.M. Mannino, R.C. Gagnon, T.L. Petty, and El Lydick Obstructive lung disease and low lung function in adults in the United States. Data from the National Health and Nutrition Examination Survey, 1988-1994 Arch Intern Med 160 2000 1683 1689
35. R. Nielsen, A. Johannessen, H.M. Schnelle, P.S. Bakke, J.E. Askildsen, and E.R. Omenaas Repeatability of health economic data in COPD Respir Med 102 2008 1556 1562
36. J.B. Soriano, W.C. Maier, P. Egger, G. Visick, B. Thakrar, and J. Sykes Recent trends in physician diagnosed COPD in women and men in the UK Thorax 55 2000 789 794
37. S.I. Rennard, and D.M. Daughton Smoking cessation Chest 117 2000 360 364